David Alberts
Direttore Tecnico/Scientifico/R&S presso Omnitura Therapeutics, Inc.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Jeffrey Dao | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 23 anni |
Francis V. Dane | M | 71 |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 23 anni |
James Dao | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 23 anni |
Peter W. Likins | M | 87 |
University of Arizona
| 27 anni |
Norman P. McClelland | M | - |
University of Arizona
| - |
Ann Weaver Hart | M | 74 |
University of Arizona
| 12 anni |
Jerry R. Norskog | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
Simon Sutcliffe | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | 15 anni |
Michael E. Hogan | M | - |
University of Arizona
| - |
Keith Runge | M | - |
University of Arizona
| - |
Joshua Johnson | M | 44 |
University of Arizona
| - |
Stephen M. Papadopoulos | M | - |
University of Arizona
| - |
Jennifer Casteix | F | - |
University of Arizona
| - |
Jamie Gutierrez | M | - |
University of Arizona
| - |
Douglas Taren | M | - |
University of Arizona
| - |
Christopher M. Hopkins | M | - |
University of Arizona
| - |
Edward H. Shortliffe | M | 76 |
University of Arizona
| 17 anni |
Vikki Dempsey | F | - |
University of Arizona
| - |
Ronald J. Richman | M | 82 |
University of Arizona
| 16 anni |
Ivo Abraham | M | - |
University of Arizona
| - |
Doo-Hwan Kim | M | - |
University of Arizona
| - |
Stephen Lam | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
Bernard Zeigler | M | - |
University of Arizona
| - |
Rodney C. Armstead | M | - |
University of Arizona
| - |
Teresa Briggs | F | 63 |
University of Arizona
| - |
Barbara K. Cone | M | - |
University of Arizona
| - |
David Smallhouse | M | - |
University of Arizona
| - |
Anthony D. Puopolo | M | 52 |
University of Arizona
| - |
Sarah Netherton | F | - |
University of Arizona
| - |
Meg Hagyard | F | - |
University of Arizona
| - |
Ruth Zollinger | F | - |
University of Arizona
| - |
Eileen McGarry | F | - |
University of Arizona
| - |
Robert Lopez-Hanshaw | M | - |
University of Arizona
| - |
Kevin M. Fitzsimmons | M | 67 |
University of Arizona
| 43 anni |
Larry Goldenberg | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
Nasser Peyghambarian | M | - |
University of Arizona
| - |
James B. Fink | M | - |
University of Arizona
| - |
Martin P. Fox | M | - |
University of Arizona
| - |
Sylvia C. Quintero | F | 65 |
University of Arizona
| - |
Joaquin Ruiz | M | 71 |
University of Arizona
| 41 anni |
Thomas M. Grogan | M | 78 |
University of Arizona
| 45 anni |
Elaine L. Jacobson | M | - |
University of Arizona
| - |
Myron K. Jacobson | M | - |
University of Arizona
| - |
David Morris Korbin | M | 82 |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
Steven Barker | M | 79 |
University of Arizona
| - |
Daniel Douglas von Hoff | M | 76 |
University of Arizona
| - |
Juha Tapani Rantala | M | - |
University of Arizona
| - |
Kerstin Block | F | - |
University of Arizona
| 18 anni |
Jack Troia | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
Mark Lautman | M | - |
University of Arizona
| - |
Ross MacLean | M | - |
University of Arizona
| - |
Christine Spiegelberg | M | - |
University of Arizona
| - |
Augusto Sasso | M | - |
University of Arizona
| - |
Stephen Golden | M | - |
University of Arizona
| - |
Barry A. Hendin | M | - |
University of Arizona
| - |
Tom E. McCandless | M | 69 |
University of Arizona
| - |
L. Ben Lytle | M | 77 |
University of Arizona
| - |
Dwight William Babcock | M | 76 |
University of Arizona
| - |
Marvin Slepian | M | 68 |
University of Arizona
| 33 anni |
Kenneth Foon | M | - |
Omnitura Therapeutics, Inc.
Omnitura Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Omnitura Therapeutics, Inc. is a biopharmaceutical company engaged in the commercialization of Multifunctional Multitargeted pharmaceuticals for oncology, a new class of therapies that is design to address the fundamentally complex and heterogeneous nature of cancer. The firm's product Aneustat, is a non-toxic, orally delivered, multivalent I-O drug candidate design to intercept, treat, and prevent cancer. The company was founded by James Dao and Jeffrey Dao in 2001 and is headquartered in Burlingame, CA. | - |
Sara Garre | F | - |
University of Arizona
| 5 anni |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Stati Uniti | 61 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- David Alberts
- Contatti personali